PE20211446A1 - Formas de co-cristales de un analogo de novobiocina y prolina - Google Patents

Formas de co-cristales de un analogo de novobiocina y prolina

Info

Publication number
PE20211446A1
PE20211446A1 PE2020001199A PE2020001199A PE20211446A1 PE 20211446 A1 PE20211446 A1 PE 20211446A1 PE 2020001199 A PE2020001199 A PE 2020001199A PE 2020001199 A PE2020001199 A PE 2020001199A PE 20211446 A1 PE20211446 A1 PE 20211446A1
Authority
PE
Peru
Prior art keywords
novobiocin
analog
prolin
crystals
forms
Prior art date
Application number
PE2020001199A
Other languages
English (en)
Spanish (es)
Inventor
Xin Jiang
John Allen Walling
Melanie J Bevill
Christopher S Seadeek
Jared P Smit
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of PE20211446A1 publication Critical patent/PE20211446A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2020001199A 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina PE20211446A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
PE20211446A1 true PE20211446A1 (es) 2021-08-05

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001199A PE20211446A1 (es) 2018-02-07 2019-02-01 Formas de co-cristales de un analogo de novobiocina y prolina

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR20240155354A (https=)
CN (2) CN112020506B (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI797249B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029369B2 (en) * 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CA2892832C (en) * 2011-11-25 2020-04-14 Nuformix Technologies Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
SMT201900660T1 (it) * 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP2890704B1 (en) * 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 l- 프롤린 화합물, 및 l- 프롤린 화합물의 모노하이드레이트 및 결정
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE

Also Published As

Publication number Publication date
TWI868593B (zh) 2025-01-01
IL276583A (en) 2020-09-30
JP2026012851A (ja) 2026-01-27
US11401294B2 (en) 2022-08-02
EA202091885A1 (ru) 2021-01-15
TWI797249B (zh) 2023-04-01
AU2022283638B2 (en) 2024-07-25
CA3226385A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
US20190241599A1 (en) 2019-08-08
MY209803A (en) 2025-08-05
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
CN112020506B (zh) 2024-10-11
AU2022283638A1 (en) 2023-02-02
MX2020008326A (es) 2020-09-28
CL2022003784A1 (es) 2023-06-09
CL2020002051A1 (es) 2021-02-19
NZ767558A (en) 2024-11-29
AR114245A1 (es) 2020-08-12
IL276583B1 (en) 2024-11-01
JP2021512910A (ja) 2021-05-20
EP3749675B1 (en) 2025-12-31
US20240043465A1 (en) 2024-02-08
KR102718111B1 (ko) 2024-10-17
US10717755B2 (en) 2020-07-21
WO2019156907A1 (en) 2019-08-15
BR112020016205A2 (pt) 2020-12-15
CA3090646C (en) 2024-02-27
TW201945381A (zh) 2019-12-01
JP2024001167A (ja) 2024-01-09
AU2019217821B2 (en) 2022-09-08
AU2024227646A1 (en) 2024-11-14
CO2020009761A2 (es) 2020-10-30
CN118894894A (zh) 2024-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
AU2019217821A1 (en) 2020-09-24
EP3749675A1 (en) 2020-12-16
KR20240155354A (ko) 2024-10-28
CA3090646A1 (en) 2019-08-15
US20200347088A1 (en) 2020-11-05
IL276583B2 (en) 2025-03-01
TW202510893A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
PE20211446A1 (es) Formas de co-cristales de un analogo de novobiocina y prolina
CL2021002959A1 (es) Nuevas formas sólidas de ácido (2s,3s,4s,5r,6s)-3,4,5-trihidroxi-6-(((4ar,10ar)-7- hidroxi-1-propil-1,2,3,4,4a,5,10,10a- octahidrobenzo[g]quinolin-6-il)oxi)tetrahidro2h-piran-2-carboxílico.
ECSP19053616A (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CL2021001877A1 (es) Compuestos moduladores de fxr (nr1h4)
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CR20220559A (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
MX2021012769A (es) Anticuerpos bloqueadores cd73.
CL2012001461A1 (es) Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras.
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
MX2019011629A (es) Nuevos compuestos que se unen a fxr (nr1h4) y modulan su actividad.
AR064809A1 (es) Formas cristalinas
CL2004000732A1 (es) Compuestos derivados de oximas sustituidas y sus sales farmaceuticamente aceptables; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los contiene; y uso de los compuestos para el tratamiento del cancer.
CL2012000583A1 (es) Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras.
AR096582A1 (es) Procesos de fabricación y formas cristalinas de un inhibidor de mdm2
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
ECSP22087958A (es) Compuestos de insulina acilada de acción temporal prolongada
FI3774745T3 (fi) Oksatsoliyhdistekide
PH12020551297A1 (en) Compounds having s1p5 receptor agonistic activity
WO2007032010A3 (en) Use of tellurium compounds for protection from ultra-violet radiation
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
CL2009000519A1 (es) Compuestos derivados de sulfonamida sustituida, como moduladores del receptor de bradicinina b1; composicion farmaceutica; y su uso para el tratamiento del dolor, migraña, diabetes, enfermedad del tracto respiratorio, enfermedad neurologica, enfermedad inflamatoria de la piel, enfermedad reumatica, obesidad, entre otras.